The board of directors of SSY Group Limited announced that the Group's Dexmedetomidine Hydrochloride has obtained the approval for registration from the National Medical Products Administration of China to become a bulk drug for the preparations on the market. As stated in the Company's announcement dated 10 September 2021, the Group has obtained the approval for drug production and registration for Dexmedetomidine Hydrochloride Injection (2ml:0.2mg) from the National Medical Products Administration of China. Dexmedetomidine is an 2 adrenergic receptor agonist, and is mainly used for sedation during tracheal intubation and mechanical ventilation of patients under general anesthesia during surgery. Dexmedetomidine Hydrochloride Injection has been included in the national medical insurance of China, and is a main type of anesthetic drug for clinical use.